Skip to search formSkip to main contentSkip to account menu

AZD9291

Known as: 2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-, AZD-9291 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

AcrylamidesAniline Compoundsosimertinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model
AZD9291 (osimertinib) is approved for standard care in patients with EGFR T790M-positive non-small cell lung cancer (NSCLC) after… 
2018
2018
Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial–mesenchymal transition phenotype
PurposeAZD9291 is an irreversible, small-molecule inhibitor which has potency against mutant EGFR- and T790M-resistant mutation… 
Review
2018
Review
2018
Osimertinib for the treatment of patients with EGFR mutation-positive non-small cell lung cancer.
Epidermal growth factor receptor (EGFR) mutations, mostly seen in exon 19 or exon 21, are present in roughly 50% of patients with… 
Review
2017
Review
2017
Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
ABSTRACT Introduction: Significant advances have been made since the development of epidermal growth factor receptor tyrosine… 
2016
2016
Follow up analysis by exosomal miRNAs in EGFR mutated non-small cell lung cancer (NSCLC) patients during osimertinib (AZD9291) treatment: A potential prognostic biomarker tool.
e23035Background: NSCLC patients harboring EGFR mutations are able to receive approved tyrosine kinase inhibitors (TKIs) but to… 
2015
2015
The Allelic Context of the C 797 S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity toSubsequent Treatment Strategies
Purpose: A secondary EGFR mutation, T790M, is the most common resistance mechanism in EGFR-mutant adenocarcinomas that have… 
2015
2015
Liquid biopsies reveal the dynamic nature of resistance mechanisms in solid tumors
Two new studies demonstrate that so-called 'liquid biopsies' may reveal important genomic information needed to monitor treatment… 
2015
2015
A randomized, phase III study (FLAURA) of AZD9291, a novel EGFR-TKI, versus gefitinib or erlotinib in treatment-naïve patients with advanced non-small cell lung cancer and an EGFR-TKI-sensitizing…
TPS8102 Background: EGFR-TKI is the recommended treatment for patients with advanced NSCLC who have an EGFR-TKI-sensitizing… 
2015
2015
AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort.
8000 Background: AZD9291 is an orally administered EGFR TK inhibitor with activity against the sensitizing EGFR mutations (EGFRm… 
2014
2014
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of technologies to support the clinical development of AZD9291.
8092 Background: EGFR tyrosine kinase inhibitors are highly effective in treating EGFR mutant+ NSCLC. Patients invariably relapse… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)